The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Non-viral vectors in cancer gene therapy: principles and progress
Abstract
This review focuses on the use of synthetic (non-viral) delivery systems for cancer gene therapy. Therapeutic strategies such as gene replacement/mutation correction, immune modulation and molecular therapy/'suicide' gene therapy type approaches potentially offer unique and novel ways of fighting cancer, some of which have already shown promise in early clinical trials. However, the specific and efficient delivery of the genetic material to remote tumors/metastases remains a challenge, which is being addressed using a variety of viral and non-viral systems. Each of these disparate systems has distinct advantages and disadvantages, which need to be taken into account when a specific therapeutic gene is being used. The review concentrates on particulate gene delivery systems, which are formed through non-covalent complexation of cationic carrier molecules (e.g. lipids or polymers) and the negatively charged plasmid DNA. Such systems tend to be comparatively less efficient than viral systems, but have the inherent advantage of flexibility and safety. The DNA-carrier complex acts as a protective package, and needs to be inert and stable while in circulation. Once the remote site has been reached the complex needs to efficiently transfect the targeted (tumor) cells. In order to improve overall transfection specificity and efficiency it is necessary to optimize intracellular trafficking of the DNA complex as well as the performance after systemic administration. Common principles and specific advantages or disadvantages of the individual synthetic gene delivery systems are discussed, and their interaction with tumor-specific and generic biological barriers are examined in order to identify potential strategies to overcome them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Ogris, M., Brunner, S., Schüller, S., Kircheis, R., & Wagner, E. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300900 · Cited by 1,178
Dash, P. R., Read, M. L., Barrett, L. B., Wolfert, M. A., & Seymour, L. W. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300843 · Cited by 386
Tseng, W.-C., Haselton, F. R., & Giorgio, T. D. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25641 · Cited by 182
Cited by
Biodegradable synthetic polymers: Preparation, functionalization and biomedical application
Tian, H., Tang, Z., Zhuang, X., Chen, X., & Jing, X. (2012) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.06.004 · Cited by 1,293
DUFES, C., UCHEGBU, I., & SCHATZLEIN, A. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.017 · Cited by 984
Self-citationProgress in developing cationic vectors for non-viral systemic gene therapy against cancer
Morille, M., Passirani, C., Vonarbourg, A., Clavreul, A., & Benoit, J.-P. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.04.036 · Cited by 769
Inorganic Nanoparticles as Carriers of Nucleic Acids into Cells
Sokolova, V., & Epple, M. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200703039 · Cited by 581
Polymers for gene delivery across length scales
Putnam, D. (2006) · Nature Materials · doi:10.1038/nmat1645 · Cited by 572
Metadata
- Authors
- Schatzlein, A. G.
- Venue
- Anti-Cancer Drugs
- Published
- 2001-04
- Volume
- 12
- Issue
- 4
- Pages
- 275-304
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W2010228315
- Cited by
- 188
- References
- 4
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-viral vectors in cancer gene therapy: principles and progress. https://app.cochat.ai/papers/10.1097/00001813-200104000-00001
- The paper
- Schatzlein, A. G. (2001). Non-viral vectors in cancer gene therapy: principles and progress. Anti-Cancer Drugs. https://doi.org/10.1097/00001813-200104000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.